Programmed death ligand 1, poly adenosine diphosphate ribose polymerase, and vascular endothelial growth factor receptor inhibition: a potential combination regimen for targeting triple-negative breast cancer? [PDF]
Int J Surg, 2023 Abdul Wahid M +5 more
europepmc +2 more sources
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer [PDF]
Therapeutic Advances in Medical OncologyPoly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have significantly improved the treatment of advanced ovarian cancer, however, there are still many aspects of their use that require further understanding.
Uma A. Mukherjee +2 more
doaj +2 more sources
Natural occurence of a biopolymer, poly (adenosine diphosphate ribose)
Nucleic Acids Research, 1977 Evidence for the natural occurrence of poly(adenosine diphosphate ribose) in vivo was obtained using a sensitive radioimmunoassay and poly(adenosine diphosphate ribose) glycohydrolase, which specifically hydrolyzes poly(adenosine diphosphate ribose).
Harutake Sakura +6 more
openalex +5 more sources
Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report. [PDF]
J Int Med Res, 2021 A 57-year-old woman was diagnosed with IDH-wildtype (IDHwt) astrocytoma (World Health Organization grade II) with the molecular characteristics of glioblastoma.
Wang Z, Ren Y, Du F, Sun Y, Jiang W.
europepmc +2 more sources
Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis [PDF]
Archives of Gynecology and Obstetrics, 2021 To investigate the efficacy and safety of poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors (including their different types) as maintenance therapy in women with newly diagnosed ovarian cancer, and to explore whether this therapy ...
Hongyan Cheng +3 more
openalex +2 more sources
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. [PDF]
CA Cancer J ClinPoly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair.
Hage Chehade C +10 more
europepmc +2 more sources
Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review. [PDF]
CureusPoly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have appeared as a revolutionary approach to treating advanced ovarian cancer, particularly in patients with breast cancer (BRCA) mutations and homologous recombination deficiency (HRD ...
Dewani D, Jaiswal A, Karwade P.
europepmc +2 more sources
Synthesis of DNA and Poly(Adenosine Diphosphate Ribose) in Normal and Chronic Lymphocytic Leukemia Lymphocytes [PDF]
Journal of Clinical Investigation, 1978 Nathan A. Berger +4 more
openalex +2 more sources
Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a
Cancer, 2016 Ursula A. Matulonis +15 more
openalex +2 more sources